Structure Therapeutics Inc ADR
Structure Therapeutics Inc ADR (GPCR) Historical Volatility
GPCR's 30 day historical volatility is 60.38%, in the 55th percentile of readings over the past year. This is an average percentile, meaning Structure Therapeutics Inc ADR shares have moved roughly in line with their typical range. GPCR's 30 day implied volatility sits at 128.13%, with an IV Rank of 94.05%, leaving IV 67.75 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 16, 2026.
Read more
Tracking GPCR historical volatility helps you see how much Structure Therapeutics Inc ADR's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, GPCR's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor GPCR 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. GPCR's 30 day historical volatility, or GPCR HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing GPCR's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF.
Historical Volatility
Historical movement is near its typical level for the past year. Neither unusually calm nor unusually active.
As of Nov 16, 2026
As of Nov 16, 2026
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →